08:26 AM EDT, 10/27/2025 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) said Monday that new data from two clinical studies of its investigational oral peptide therapy, icotrokinra, in patients with ulcerative colitis and plaque psoriasis demonstrated clinically meaningful outcomes.

In a phase 2b trial of icotrokinra in patients with ulcerative colitis, 31.7% of patients achieved clinical remission and 38.1% showed endoscopic improvement at week 28, the company said.

Protagonist Therapeutics ( PTGX ) said Johnson & Johnson ( JNJ ) has initiated a phase 3 trial of icotrokinra in adults and adolescents with moderate to severe active ulcerative colitis and a phase 2b/3 trial in Crohn's disease.

Separately, 72% of patients with scalp psoriasis and 85% with genital psoriasis achieved site-specific clear or almost clear skin at week 52 in a phase 3 trial, Protagonist Therapeutics ( PTGX ) said.

The company said 67% of all patients achieved clear or almost clear skin by week 24, maintained through week 52.

Shares of Protagonist Therapeutics ( PTGX ) were up 1.6% in recent Monday premarket activity.